Course

CSIE - Hematology Oncology ACE (LIVE)

Ended Oct 21, 2022
2 credits

Sorry! The enrollment period is currently closed. Please check back soon.

Full course description

Objectives

At the conclusion of this activity, learners will be able to:

  1. Develop a clinical approach to the chief complaint of easy bleeding/bruising.
  2. Name the organ systems commonly associated with easy bleeding/bruising.
  3. Develop a differential diagnosis for easy bleeding/bruising based on history, physical exam findings, and diagnostic tests.
  4. List common causes of easy bleeding/bruising in a younger versus an older patient.
  5. List child abuse as a potential cause of brusing.
  6. List Senile Purpura as a common benign form of bruising in the elderly patient.
  7. List major life threatening causes of easy bleeding/bruising.
  8. Identify the physical exam findings indicative of severe bleeding.
  9. Differentiate between different causes of easy bleeding/bruising (e.g. Von Willebrand disease, vs hemophilia, vs ITP, TTP, DIC, leukemia, child abuse etc.) given key clinical features.
  10. Identify appropriate diagnostic testing to further evaluate easy bleeding/bruising.
  11. Identify the common hematologic laboratory abnormalities associated with bleeding disorders.

ACCREDITATION

Texas A&M University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION

Texas A&M University College of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE

The faculty for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

PLANNERS DISCLOSURES

The planners for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.